Immuno-oncology

Conference Coverage

Nivolumab boosts overall survival in HCC

BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...

MD IQ

Pages